$4 a share: Curaleaf's formal offer for Aurora Cannabis is now public, taken directly to Aurora shareholders on Monday after private talks between Curaleaf CEO Boris Jordan and Aurora CEO Miguel Martin broke down earlier this summer. The price carries a 45% premium to Aurora's 30-day average share price through August 10, the pre-announcement baseline Curaleaf used.
| Metric | Figure | Status |
|---|---|---|
| Offer price | $4.00 per share | Reported |
| Premium to 30-day avg (Aug 10 base) | ~45% | Reported |
| Projected annual cost savings | ~$40M | Curaleaf (projected) |
| Projected combined market cap | ~$3B | Curaleaf (projected) |
| Aurora intraday | +1.5% | Reported, Monday |
| Curaleaf intraday | -2% | Reported, Monday |
Curaleaf's core pitch pairs the immediate premium with access to the U.S. consumer cannabis market, which Curaleaf says is the world's largest. The company projects a combined entity it characterizes as the primary vehicle for institutional investors seeking legal cannabis exposure. Aurora's board has formed a special committee to review the terms; no recommendation has been issued.
What Curaleaf is actually paying for
The premium buys EU certification. Aurora, a Canadian cannabis company, holds Good Manufacturing Practice-certified cultivation capacity, the required credential for medical cannabis exports into European Union markets. Germany, with a population of about 84 million and strict standards on how imported medical cannabis is grown and tested, is the principal target. Federal restrictions effectively bar U.S. operators such as Curaleaf from direct cannabis export, which makes acquiring existing certified capacity the faster route.
Curaleaf's press release is pointed about Aurora's track record. The company calls it "a sustained track record of value destruction" and cites C$4.56 billion in impairment charges Aurora recognized between 2020 and 2026. Jordan said he initially sought a friendly approach; direct talks with Martin stalled before he went to shareholders.
Hostile bids of this structure fail more often than they close. Aurora's special committee is now reviewing the offer, with no recommendation yet issued. Jordan said Curaleaf has contingency plans, framing the fallback as building European market presence rather than acquiring it. No cost or timeline was attached.